论文信息 - Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study. - 字舞流文

Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.

Gregory Riely | E. Felip | P. Janne | S. Ramalingam | J. Yang | Sang-We Kim | T. Mekhail | T. Kim | Jianchang Lin | Caicun Zhou | D. Nguyen | V. Bunn | M. G. García Campelo | H. Lin | S. Vincent | S. Jin | M. Mehta